Cerivastatin, genetic variants, and the risk of rhabdomyolysisKristin D Marciante
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA
Pharmacogenet Genomics 21:280-8. 2011
..The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis...
Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic strokeKristin D Marciante
Cardiovascular Health Research Unit, Seattle, Washington 98101, USA
Pharmacogenet Genomics 18:535-43. 2008
..We conducted a population-based, case-control study at Group Health to determine whether common genetic variation in the CYP2J2, CYP2C8, and CYP2C9 genes was associated with the risk of myocardial infarction and ischemic stroke...
Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patientsKristin D Marciante
Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA
Am J Epidemiol 166:19-27. 2007
..17). In this case-control study, RAS gene haplotypes were not significantly associated with increased risks of myocardial infarction or stroke...
- Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke
Lucia A Hindorff
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
Pharmacogenet Genomics 18:677-82. 2008
....
- Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke
Joshua C Bis
Department of Medicine, University of Washington, Seattle, WA 981041, USA
Atherosclerosis 198:166-73. 2008
....
- beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke
Rozenn N Lemaitre
Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA
Am J Hypertens 21:290-6. 2008
..The benefits of beta-blocker therapy may depend on underlying genetic susceptibility...
- Association of genetic variations with nonfatal venous thrombosis in postmenopausal women
Nicholas L Smith
Department of Epidemiology, University of Washington, Seattle, WA 98101, USA
JAMA 297:489-98. 2007
....
- Human liver expression of CYP2C8: gender, age, and genotype effects
Suresh Babu Naraharisetti
Departments of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
Drug Metab Dispos 38:889-93. 2010
..CYP2C8 mRNA or protein expression levels were not significantly affected by CYP2C8*3 or *4 genotype, gender, or age, and variation observed clinically in CYP2C8 activity warrants further investigation...
- Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5
Rüdiger Kaspera
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
Biochem Pharmacol 82:681-91. 2011
..In silico studies illustrate the genetic differences between wild type and variant on the molecular level...
- Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction
Nona Sotoodehnia
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA
Nat Genet 42:1068-76. 2010
..These findings extend our current knowledge of ventricular depolarization and conduction...
- Logic regression for analysis of the association between genetic variation in the renin-angiotensin system and myocardial infarction or stroke
Charles Kooperberg
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Am J Epidemiol 165:334-43. 2007
....
